Cite
HARVARD Citation
Di Legge, A. et al. (2011). Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer. International journal of gynecological cancer. 21 (8), pp. 1446-1451. [Online].